BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION

    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, customers, and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2023 and 2022.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.

    As of March 31, 2023, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.

    The following table is a summary of segment information for the three months ended March 31, 2023 and 2022. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2022 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.

	Three Months Ended March 31,
	2023		2022
Net revenues:
DIS business	$	2,259	$	2,541
All other operating segments	72		70
Total net revenues	$	2,331	$	2,611
Operating earnings (loss):
DIS business	$	374	$	562
All other operating segments	8		7
General corporate activities	(77)		(56)
Total operating income	305		513
Non-operating expense, net	(28)		(61)
Income before income taxes and equity in earnings of equity method investees	277		452
Income tax expense	(65)		(110)
Equity in earnings of equity method investees, net of taxes	5		31
Net income	217		373
Less: Net income attributable to noncontrolling interests	15		18
Net income attributable to Quest Diagnostics	$	202	$	355

    The approximate percentage of net revenues by major service for the three months ended March 31, 2023 and 2022 were as follows:

	Three Months Ended March 31,
	2023		2022
Routine clinical testing and other services	49	%	41	%
COVID-19 testing services	5		23
Gene-based and esoteric (including advanced diagnostics) testing services	37		28
Anatomic pathology testing services	6		5
All other	3		3
Net revenues	100	%	100	%